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Joanne M Langley2,3,4, Scott A Halperin2,3,4* and Maritime Universal Rotavirus Vaccination Program (MURVP)Abstract
Background: Rotavirus vaccine is recommended for all infants in Canada. To evaluate the logistics of implementing
a universal rotavirus vaccination program, we compared the effectiveness of program implementation in
jurisdictions with either a physician-administered or public health nurse-administered program.
Methods: All infants born between October 1, 2010 and September 30, 2012 in Prince Edward Island and Nova
Scotia’s Capital District Health Authority were eligible for the vaccination program. A universal rotavirus vaccination
program was implemented and delivered in public health clinics in Prince Edward Island and in physicians’ offices
in Nova Scotia.
Results: Engagement of vaccinators in delivery of the universal vaccination program was more successful in Prince
Edward Island than in Nova Scotia. Vaccine coverage rates rose rapidly in Prince Edward Island, exceeding 90% for
both doses within 3 months and remaining at those levels over the two-year program. In contrast, coverage rates
in Nova Scotia rose more slowly and never exceeded 40% during the two years. Access to coverage data was more
timely and accurate in Prince Edward Island than Nova Scotia.
Conclusion: A universal rotavirus vaccination program delivered through public health clinics achieved more rapid
and higher levels of coverage than a program administered through physicians’ offices.
Trial registration: NCT01273077.
Keywords: Rotavirus infection, Rotavirus vaccine, Immunization program, Immunization delivery models,
Program evaluationBackground
Rotavirus is the most common cause of infectious gastro-
enteritis in infants, estimated to cause millions of hospi-
talizations and from 450,000 to 550,000 deaths annually
worldwide [1-3]. Rotavirus infections tend to cause more
severe illness in children than other gastrointestinal
pathogens; dehydration requiring medical intervention is
common [4]. In Canada and other industrialized countries,
deaths resulting from rotavirus occur rarely, although
hospitalizations, emergency room visits, and physician
visits frequently occur [5]. Hospital-based surveillance in* Correspondence: scott.halperin@dal.ca
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(IMPACT) demonstrated that 48.6% of hospitalized chil-
dren had dehydration and 7% experienced seizures [6];
most children were previously healthy, without underlying
medical conditions.
Two orally administered rotavirus vaccines are available
in Canada for the prevention of rotavirus infection:
RotaTeqW (Merck Frosst Canada) and RotarixW (Glaxo-
SmithKline). Approved in 2006, RotaTeqW is a bovine hu-
man reassortant vaccine comprising the P1A [8] genotype
and serotypes G1, G2, G3, and G4 [7] administered as a 3-
dose schedule. Approved in 2008, RotarixW is a live, attenu-
ated human G1P1A [8] rotavirus strain administered as a
two-dose schedule [8]. Both vaccines were safe and effect-
ive in large, field efficacy studies [9,10]. Both vaccines arel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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National Advisory Committee on Immunization (NACI)
[11] and for inclusion in universal immunization programs
by the Canadian Immunization Committee [12].
Public funding for universal programs did not imme-
diately follow the NACI recommendations because of
remaining unknowns about the burden of illness of
rotavirus in Canada, the effectiveness of the vaccine in a
Canadian context, and the acceptability of a universal pro-
gram amongst health care providers and the public, des-
pite Canadian data suggesting that the vaccines would be
cost-effective [13,14]. We undertook a population-based
intervention in three Canadian jurisdictions to provide
additional Canadian data on the feasibility, acceptability,
and effectiveness of implementing a publicly funded
universal rotavirus vaccination program (URVP). Two
implementation methods were compared with a control
(no URVP). The objective was to evaluate the logistics of
implementing a URVP and compare the effectiveness of
the program implementation in jurisdictions with either a




The study took place in three health regions in the Mari-
time Provinces. There were two intervention areas
(Prince Edward Island [PEI] and Capital District Health
Authority of Nova Scotia [CDHA/NS]) and one non-
intervention control area (the Saint John zone of the
Horizon Health region of New Brunswick [SJ/NB]). In
2011, PEI had an annual birth cohort of 1432 [15] with
all publicly funded immunizations provided by public
health nurses in public health immunization clinics. The
2011 annual birth cohort of CDHA/NS was estimated to
be 4209 (Atlee Perinatal Database, IWK Health Centre,
Halifax, NS, personal communication) and most immu-
nizations are provided by family physicians. The birth
cohort of SJ/NB was 1757 [16] and most immunizations
are provided by family physicians. The study was
approved by the Research Ethics Boards of the IWK
Health Centre, Halifax, NS, Health PEI, Charlottetown,
PEI, and Horizon Health, Saint John, NB. (clinicaltrials.
gov NCT01273077).
Participants and interventions
All infants who resided in PEI and in CDHA/NS born bet-
ween October 1, 2010 and September 30, 2012 were eli-
gible to participate in the URVP. The non-intervention
region, SJ/NB, was included in the surveillance of rota-
virus-related hospitalizations but was not considered fur-
ther in this program implementation analysis. Rotavirus
vaccine (RotarixW, GlaxoSmithKline, Canada) was pro-
vided to the jurisdictions at no charge. The URVP wasimplemented according to the standard practices for
introducing a new, publicly funded vaccination program.
In PEI, this begins with development of a proposal by the
Chief Public Health Office Immunization Committee
using a decision-making framework that includes multiple
programmatic factors including epidemiology and disease
burden, nature of the vaccine, and cost-effectiveness
[17]. Following consultation with Health PEI regarding
implementation issues, the proposed new immunization
program typically is submitted to the provincial Treasury
Board for funding approval. Once approved, the
immunization program is implemented through Public
Health Nursing. The implementation process includes an
education in-service with immunizing public health
nurses, notification of physicians and nurse practitioners
of the new program, development and distribution of fact
sheets to the public and promotional material to physi-
cians and nurse practitioners, and engagement of the
media. In Nova Scotia, vaccine programs are introduced
following a recommendation from the Immunization Sub-
Committee and approval of the full Communicable Dis-
ease Prevention and Control Committee. Proposals for
programs are then submitted to the Provincial Treasury
Board during the annual budgetary approval cycle. Once
government approval is received, information and educa-
tional material is distributed to health care providers who
administer vaccine (mostly primary care physicians). For
the URVP in CDHA/NS, the program decision was made
at the district level with provincial support for participat-
ing in the demonstration project. Provider education was
provided subsequent to an education needs assessment,
face-to-face and webinar delivered continuing education
sessions, direct interaction and discussion with group
practices, engaging physicians in project working groups,
mailed and electronic communication with physicians,
information sheets included with delivery of other routine
pediatric vaccines, and media releases directed at the pub-
lic and providers. In PEI, rotavirus vaccine was primarily
administered along with other routine pediatric vaccines
by public health nurses in public health clinics distributed
across the province. In CDHA/NS, rotavirus vaccine was
provided to family physicians by public health along with
other routine pediatric vaccines and was administered in
family physicians’ offices. As the rotavirus program was
implemented as a public health provided program, con-
sent for vaccination in both jurisdictions was obtained
from parents/guardians as per other routinely adminis-
tered childhood vaccines.
Outcomes and data analysis
Program effectiveness was monitored by measuring vac-
cine coverage for the first and second dose of rotavirus
vaccine in PEI and CDHA/NS; vaccine coverage was not
assessed in SJ/NB where no intervention was undertaken.
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fants who received the first and second doses of rotavirus
vaccine. In PEI, this was determined using the provincial
vaccine registry of doses administered in public health
clinics and the annual birth cohort each year. In CDHA/
NS, vaccine coverage was measured by the annual birth
cohort and the number of doses administered by family
physicians as reported either on paper-based or electronic
reciprocal notification forms whereby physicians reported
who received the vaccine doses provided to them by
public health. Insights into the program implementation
process were obtained by key informant interviews with
public health individuals in PEI and CDHA/NS respon-
sible for implementation of the URVP following comple-
tion of the intervention project.
Vaccine impact was evaluated by surveillance for
rotavirus-related emergency room visits and hospita-




In PEI, the program implementation activities were
qualitatively similar to other new provincial vaccina-
tion programs. The in-service education session for all
immunizing public health nurses was attended by 43
(97.7%) of the 44 eligible practitioners. Promotional ma-
terial about the program was also provided to all physi-
cians and nurse practitioners, although they were not
involved in the administration of the vaccine. Fact sheets
were provided to parents of all newborn infants and
again at public health vaccination clinics. The program
was announced in the legislature, through the public











Figure 1 Vaccine coverage by month for dose 1 (blue lines) and dosetwo members of the District Department of Family Medi-
cine participated in the program implementation planning
committee. Notices describing the new program were sent
to all physicians and nurse practitioners and fact sheets
were provided at the time of delivery to mothers of all
newborn infants. Posters were distributed to physicians’
offices, the public health website was updated, and promo-
tional information was included with all other routine
pediatric vaccine orders shipped to physician offices. The
needs assessment engaging the 405 practicing physicians
in CDHA/NS was completed by 6 (1.5%) practitioners. A
face-to-face education session was attended by 8 (2.0%) of
the 405 family physicians, and an additional 3 (0.7%) phy-
sicians participated in an educational webinar (of note, the
webinar was also attended by 10 CDHA/NS public health
nurses who were interested in the program but were not
involved in administering the vaccine to infants).
Vaccine coverage
Vaccine coverage in PEI rose quickly after implementa-
tion of the program and was maintained at over 90%
during the two-year program (Figure 1). Vaccine cover-
age for dose one in year one was 94.4% and 91.6% for
dose 2. In year two, vaccine coverage for dose one and
two was 95.1% and 91.7%, respectively. The slightly
lower rates for dose 2 coverage were reported by PEI
public health to be due to strict adherence to the age
limit for the first and second dose as specified in the
vaccine product monograph.
In CDHA/NS, according to reciprocal notifications
received of doses administered, vaccine coverage rose
over the first year to approximately 31.8% for dose
one and 29.5% for dose two and continued to increase
slowly in year two to 38.1% and 33.7% for doses one2 (red lines) in PEI (solid lines) and CDHA/NS (dashed lines).
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stantially more vaccine was shipped to family physicians’
offices than were reported as administered via reciprocal
notification forms, so the vaccine coverage reported is
likely an underestimate of the actual vaccine uptake. The
maximum vaccine coverage in CDHA/NS by assuming
that all shipped doses were administered to eligible infants
would be 52.8% in year one and 48.9% in year 2; however,
the latter figures are clearly overestimates since they
would include vaccine wastage and doses still stored in
physicians’ offices.
Key informant interviews
Telephone interviews were conducted with five key infor-
mants from PEI and three from CDHA/NS including four
physicians and four nurse public health officials. The
implementation of the URVP in PEI was described as
smooth and consistent with other public health vaccine
programs, rapidly achieving levels of acceptance of es-
tablished programs. Factors identified as critical to the
success were provincial support of the province-wide pro-
gram, a presumption that the URVP would be continued
beyond the term of the project (i.e., introduced as part of
the provincially funded routine pediatric vaccination
schedule), and public health nurse delivery of the vaccine
program through their established, geographically distrib-
uted, public health office sites and satellite clinics. The
major challenge identified was the novelty of an upper
limit to the age of vaccination resulting in some infants
being too old for their second dose when they arrived at
the office for their 4-month immunizations. This mostly
occurred early in the program when staff was adjusting to
the strict administration schedule for the vaccine and the
time urgency of rescheduling missed appointments. In
contrast, program implementation in CDHA/NS was
described as challenging, with a number of factors contri-
buting to the low rates of vaccine uptake. Despite substan-
tial efforts to communicate with family physicians using
multiple and redundant mechanisms, many physicians
continued to be unaware of the program and did not offer
vaccine to their patients. While interviewees described this
as a common problem with physicians for all new pro-
grams, exacerbating factors that were identified included
the lack of a province-wide program and that all com-
munication was done by the District (CDHA) without
provincial support/reinforcement. Insufficient physician
reimbursement for vaccine administration was also identi-
fied as a factor resulting in physicians either not offering
the vaccine to their patients or providing the vaccine but
not reporting back the number of doses administered
using reciprocal forms. The lack of presumption that the
program would continue after two years was also identi-
fied as a potential disincentive for physicians to provide
the vaccine to their patients.Discussion
This report describes the first URVP implemented in
Canada and compares and contrasts the success of two
different vaccine delivery systems (public health clinics
and family physicians’ offices). In PEI, where rotavirus
vaccine was delivered primarily by public health nurses
in province-wide public health offices and satellite loca-
tions, implementation proceeded smoothly and vaccine
uptake was rapid, quickly achieving coverage rates in
excess of 90% for both the first and second doses. In
contrast, in CDHA/NS where vaccine was administered
in family physician offices, program implementation was
plagued by lack of awareness by physicians and care-
givers, despite extensive efforts to engage their participa-
tion, inform them about the program, and provide them
with the necessary tools to provide the vaccine to their
patients. As a result, vaccine uptake was suboptimal and,
at the end of the two-year program, still lagged far below
other routine pediatric immunizations. A potential con-
tributing factor to the better vaccine coverage in PEI
compared to CDHA/NS is that the program in PEI was
province-wide whereas in NS it was limited to a single
district. However, CDHA/NS is home to nearly 50% of
the provincial population in NS and the implementation
methods employed mirrored those methods routinely
used for province-wide programs. Although the vaccine
was provided to physicians at no cost, there were con-
cerns about inadequate compensation to the physicians
for vaccine administration. Because rotavirus vaccine
was the first orally delivered vaccine available in NS,
there was no established reimbursement rate for this ac-
tivity. In consultation with local physician leaders, a rate
of 50% of the rate provided for injectable vaccines was
established; however, this may not have been deemed
sufficient by some practicing physicians.
In comparing the implementation successes of the two
programs, it may be that, despite the logistical barriers,
the vaccine coverage achieved in CDHA/NS may be typ-
ical for new vaccine programs in a physician-delivered or
mixed public health/physician-delivered system. In the
United States, rotavirus was recommended for universal
infant programs in 2006 [18]. In 2009, the first year for
which data are available in the National Immunization
Survey, vaccine coverage was only 43.9% among children
19–36 months of age, rising to 59.2% in 2010, 67.3% in
2011, and 68.6% in 2012 [19]. This slow rate of increase in
vaccine coverage is typically observed in the US. Human
papillomavirus vaccine (HPV) was recommended for uni-
versal immunization of pre-adolescent girls in the US in
2007 [20] and in 2008, vaccine coverage for the first dose
was 37.2% and the third dose 17.9%. Coverage rates rose
by 5–10% per year and by 2011 coverage was reported as
53.0% for dose 1 and 34.8% for dose 3; no further increase
in coverage was reported in 2012 [21]. Similar coverage
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grams have been reported in the US for other vaccines in-
cluding pneumococcal conjugate and varicella vaccines
[22]. In contrast, in Finland, vaccinations are given by
public health nurses in public health clinics or in schools
[23]. Rotavirus vaccine was offered to all infants beginning
in September 2009 and achieved vaccine coverage rates in
excess of 95% during the first two years of the program,
comparable to other vaccines in their universal infant pro-
gram [24].
In Nova Scotia where human papillomavirus vaccine is
administered by public health nurses in school-based
programs, vaccine coverage rates after the first three
doses was 85.3%, 81.2%, and 77.1%, respectively in 2008,
one year after implementation of the program [25].
Three years later in 2011, coverage rates had risen to
92.3%, 83.4%, and 76.1% for the three doses. No data are
available about the coverage rates in Nova Scotia of
other recently introduced physician-administered pub-
licly funded vaccine programs (conjugate meningococcal
vaccine, varicella vaccine, pneumococcal conjugate vac-
cine). In PEI, vaccine coverage with the rotavirus vaccine
is similar to their success with other recent universal
vaccine programs, all of which are administered by pub-
lic health nurses. For example, with meningococcal con-
jugate vaccine given to infants at 12 months of age,
vaccine coverage was 93% in the year following imple-
mentation of the program and has maintained a level of
at least 90% since that time. With HPV vaccine, coverage
rates after the first three doses was 87.6%, 84.9%, and
81.1%, respectively, one year after implementation of the
program. Four years later, coverage rates had risen to
90.7%, 90.3%, and 87.3% for the three doses.
Rapid uptake of vaccines in publicly funded programs
can be successfully accomplished in physician office-
delivered programs. In the United Kingdom where child-
hood vaccines are provided by general practitioners,
pneumococcal conjugate vaccine was introduced into the
universal vaccination program in 2006 and vaccine cover-
age of 83.7% was achieved for the primary series by
12 months of age after the first year, rising to 91% in the
second year [26]. The nature and perception of the infec-
tion, disease, and vaccine may play a role in how rapidly
vaccine coverage is achieved. Vaccine coverage targets for
practices and financial incentives for meeting those targets
may also contribute to the success observed in the UK
[27]. Rotavirus vaccine was introduced into the UK pub-
licly funded vaccine program in 2013; first-year coverage
data won’t be available until late 2014.
Although high rates of vaccine coverage can be
achieved in physician-delivered programs, as we found
in this study, the rise in vaccine coverage rates appears
to be more uniformly rapid in public health nurse-
delivered programs. An additional benefit of publichealth delivered programs is the precision of vaccine
coverage estimates, particularly in the absence of vaccine
registries. In CDHA/NS, the rotavirus vaccine coverage
rates achieved are bracketed between vaccine doses that
were reported as given and vaccine doses that were pro-
vided to physicians. In contrast, the coverage rates pro-
vided by PEI are precisely as reported.
As a result of the high coverage rates achieved in PEI,
hospitalizations related to rotavirus virtually disappeared
from the province. In contrast, there was a less dramatic
effect of the URVP in CDHA/NS (unpublished data,
manuscript submitted). This may be a contributing fac-
tor to the decision by the PEI Department of Health and
Wellness to continue the URVP after completion of this
project. In contrast, NS remains one of 5 Canadian pro-
vinces without a URVP.Conclusion
In Canada, there is no uniformity about how childhood
vaccines are delivered among the provinces or even by dis-
trict within a province. For example, childhood vaccines
are delivered primarily by public health nurses in PEI and
Alberta whereas in Nova Scotia and New Brunswick, vac-
cines are provided by public health nurses in some districts
and physicians in other districts. Although the program-
matic advantages of public health delivered childhood vac-
cines appears clear, questions about the relative costs of
the two delivery systems or the costs of changing from a
physician-delivered to a public health nurse-delivered pro-
gram have not been established. Public attitudes and pre-
ferences also have not been fully explored and, given the
increasing numbers and complexities of the childhood vac-
cination schedule, it is difficult to determine what provider
preferences are for the ideal vaccine delivery system for
the future. Further research and analysis regarding the ap-
propriate use of resources, personnel, cost, outcomes, and
accessibility are needed.
Competing interest
The authors declare that they have no competing interests. SAH, JML, and
SAM have served as consultants on ad hoc advisory boards organized by
GlaxoSmithKline who provided funding for this study.
Authors’ contributions
MZ, AN, and CR participated in the collection of the data and drafting of the
manuscript. CS participated in the collection of the data, drafting of the
manuscript, and data analysis. BH and DM participated in the design of the
study, collection of the data, and drafting of the manuscript. JL and SH
participated in the design of the study, drafting the manuscript, and data
analysis. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Deanne Burnett, Katherine Gaudreau, Michelle Lafford,
Heather Morrison, Lamont Sweet, Shirley Urquhart, Kristine Weber, Jacqueline
Fraser, the Prince Edward Island Public Health Nurses, and the Nova Scotia
District 9 family physicians for their contributions to this study. The study
was funded by an investigator-initiated grant from GlaxoSmithKline, Canada.
Zelman et al. BMC Public Health 2014, 14:908 Page 6 of 6
http://www.biomedcentral.com/1471-2458/14/908MURVP Authors
Beth A. Halperin (Dalhousie University), Scott A. Halperin (Dalhousie
University), Joanne M. Langley (Dalhousie University), Donna MacDougall
(Saint Francis Xavier University), Donna MacKinnon-Cameron (Dalhousie
University), Shelly A. McNeil (Dalhousie University), Anne Neatby
(PEI Department of Health and Wellness), Pam Publicover-Brouwer
(Dalhousie University), Carol Lynn Raithby (Capital Health, NS), Corinne
Rowswell (PEI Department of Health and Wellness), Carolyn Sanford
(PEI Department of Health and Wellness), Caryll Tawse (Capital Health, NS),
Gaynor Watson-Creed (Capital Health, NS), Noella Whelan (Capital Health,
NS), Mitchell Zelman (PEI Department of Health and Wellness).
Author details
1Department of Health and Wellness, Charlottetown, Prince Edward Island,
Canada. 2Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada.
3Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
4IWK Health Centre, Halifax, Nova Scotia, Canada. 5School of Nursing, Saint
Francis Xavier University, Antigonish, Nova Scotia, Canada.
Received: 10 May 2014 Accepted: 26 August 2014
Published: 2 September 2014
References
1. World Health Organization: Estimated rotavirus deaths for children under 5 years
of age. 2014. http://www.who.int/immunization/monitoring_surveillance/
burden/estimates/rotavirus/en/index.html. Accessed 28 January 2014.
2. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D,
Birmingham M, Glass RI: Global mortality associated with rotavirus disease
among children in 2004. J Infect Dis 2009, 200:S9–S15.
3. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD,
WHO-coordinated Global Rotavirus Surveillance Network: 2008 estimate of
worldwide rotavirus-associated mortality in children younger than 5 years
before the introduction of universal rotavirus vaccination programmes:
a systematic review and meta-analysis. Lancet 2012, 12:136–141.
4. Bernstein DI: Rotavirus overview. Ped Infect Dis J 2009, 29:S50–S53.
5. Senecal M, Brisson M, Lebel MH, Yaremko J, Wong R, Gallant LA: Measuring
the impact of rotavirus acute gastroenteritis (MIRAGE): a prospective
community-based study. Can J Infect Dis Med Microbiol 2008, 19:397–404.
6. Le Saux N, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW, for members
of the Canadian Immunization Monitoring Program, Active (IMPACT):
Substantial morbidity for hospitalized children with community-acquired
rotavirus infections: 2005-2007 IMPACT surveillance in Canadian
hospitals. Ped Infect Dis J 2010, 29:879–892.
7. Clark HF, Offit PA, Ellis RW, Eiden JJ, Krah D, Shaw AR, Pichichero M, Treanor
JJ, Borian FE, Bell LM, Plotkin SA: The development of multivalent bovine
rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996,
174:S73–S80.
8. Bernstein DI, Sack DA, Rothstein E, Reisinger K, Ward RL: Efficacy of live,
attenuated human rotavirus vaccine 89-12 in infants. Lancet 1999,
354:287–290.
9. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez
Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD,
Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L,
Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego
JW, Offit PA, Heaton PM, Rotavirus Efficacy and Safety Trial (REST) Study
Team: Safety and efficacy of a pentavalent human-bovine (WC3)
reassortant rotavirus vaccine. N Engl J Med 2006, 354:23–33.
10. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice
F, Han HH, Damaso S, Bouckenooghe A: Efficacy of human rotavirus
vaccine against rotavirus gastroenteritis during the first 2 years of life in
European infants: randomized, double-blind controlled study. Lancet
2007, 370:1757–1763.
11. National Advisory Committee on Immunization: Rotavirus Vaccine.
In Canadian Immunization Guide. 2014. http://www.phac-aspc.gc.ca/
publicat/cig-gci/p04-rot-eng.php. Accessed 30 January 2014.
12. Canadian Immunization Committee: Recommendations for rotavirus
immunization programs. ; 2014. http://www.phac-aspc.gc.ca/publicat/ccdr-
rmtc/14vol40/dr-rm40-02/dr-rm40-02-rota-eng.php. Accessed 30 January 2014.
13. Fisman DN, Chan CH, Lowcock E, Naus M, Lee V: Effectiveness and
cost-effectiveness of pediatric rotavirus vaccination in British Columbia:
a model-based evaluation. Vaccine 2012, 30:7601–7607.14. Coyle D, Coyle K, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW, Le
Saux N: Cost effectiveness of infant vaccination for rotavirus in Canada.
Can J Infect Dis Med Microbiol 2012, 23:71–77.
15. Statistics Canada: Births and total fertility rate, by province and territory. 2014.
http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/hlth85a-eng.
htm. Accessed 9 February 2014.
16. Statistics New Brunswick: Live Births by Age of Mother and Health Region of
Residence, New Brunswick. 2011. http://www.snb.ca/e/1000/1000-01/pdf-2011/
T7-1B.pdf. Accessed 9 February 2014.
17. Erickson LJ, De Wals P, Farand L: An analytical framework for
immunization programs in Canada. Vaccine 2005, 23:2470–2476.
18. Parashar UD, Alexander JP, Glass RI: Prevention of rotavirus gastroenteritis
among infants and children. Recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006,
55(RR12):1–13.
19. Centers for Disease Control and Prevention: National, State, and Local Area
Vaccination Coverage Among Children Aged 19–35 Months— United
States, 2012. MMWR Morb Mortal Wkly Rep 2013, 62:733–740.
20. Centers for Disease Control and Prevention: Recommendations of the
Advisory Committee on Immunization Practice (ACIP). Quadrivalent
human papillomavirus vaccine. MMWR Recomm Rep 2007, 56(RR02):1–24.
21. Centers for Disease Control and Prevention: National Immunization Survey-
Teen Data (Adolescents-Teens 13-17 years of age. 2014. http://www.cdc.gov/
vaccines/imz-managers/coverage/nis/teen/index.html. Accessed 1 March
2014.
22. Centers for Disease Control and Prevention: Vaccine-specific coverage among
children 19-35 months, National Immunization Survey, 1994-2012. 2014.
http://www.dcd.gov/vaccines/imz-managers/coverage/nis/child/index.html.
Accessed 1 March 2014.
23. Rapola S: National immunization program in Finland. Int J Circumpolar
Health 2007, 66:382–389.
24. Leino T, Ollgren J, Salo H, Tiihonen P, Kilpi T: First year experience of
rotavirus immunization program in Finland. Vaccine 2012, 31:176–182.
25. Population Health Assessment and Surveillance: School-based immunization
coverage in Nova Scotia: 2008-09 to 2011-12. Nova Scotia: Department of
Health and Wellness; 2013. http://novascotia.ca/dhw/populationhealth/.
Accessed 1 March 2014.
26. Public Health England: Annual vaccine coverage statistics: England. In
NHS Immunisation Statistics England 2012-13. 2014. http://www.hscic.gov.uk/
catalogue/PUB11665/nhs-immu-stat-eng-2012-13-rep.pdf. Accessed 1 March
2014.
27. Amirthalingam G, Gupta S, Campbell H: Pertussis immunisation and
control in England and Wales, 1957 to 2012: a historical review.
Euro Surveill 2013, 18:1–8.
doi:10.1186/1471-2458-14-908
Cite this article as: Zelman et al.: Implementation of a universal
rotavirus vaccination program: comparison of two delivery systems.
BMC Public Health 2014 14:908.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
